"....With respect to future perspectives, studies on tumor recurrence
and mortality are important. All studies have shown that early
detection of breast cancer, especially by MRI screening, is
realistic, although only the Dutch and Norwegian studies had
(nonrandomized) control groups. However, a downward shift of
stage as a surrogate end point does not guarantee a survival
benefit due to potential lead time and length time bias. Therefore,
and in few of the absence of randomized trials, large prospective
observational studies with long-term follow-up (

10 years) are
needed to describe concrete survival effects on mortality reduction
by screening, rather than rely on outcomes calculated by computer
models based on tumor stage. Furthermore, the (potential) long-term
adverse effects of yearly MRI screening for longer than 25 to
35 years from the age of 25 to 30 have to be evaluated, especially
in regard to possible development of contrast-induced nephropathy."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.